TheraVectys Immunize Revenue and Competitors
Estimated Revenue & Valuation
- TheraVectys Immunize's estimated annual revenue is currently $3.4M per year.
- TheraVectys Immunize's estimated revenue per employee is $155,000
Employee Data
- TheraVectys Immunize has 22 Employees.
- TheraVectys Immunize grew their employee count by 5% last year.
TheraVectys Immunize's People
Name | Title | Email/Phone |
---|
TheraVectys Immunize Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is TheraVectys Immunize?
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology' and IP's versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
keywords:N/AN/A
Total Funding
22
Number of Employees
$3.4M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $36.5M | 158 | -3% | N/A |
#2 | $51.1M | 365 | 13% | N/A |
#3 | $35M | 577 | 4% | N/A |